Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Injectable Nanomedicines Market is Expected to Witness Significant Growth With CAGR Pegged at 8.1% Through 2026: Persistence Market Research


News provided by

Persistence Market Research Pvt. Ltd.

05 Feb, 2019, 14:30 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, Feb. 5, 2019 /PRNewswire/ -- The growth of the injectable nanomedicines market is attributed to the growing use of liposomal drugs and increase in treatment seeking population across the globe. According to a latest research by the company, the global liposomes market is expected to account for revenues over US$ 300 Mn in terms of value by 2026 end. Injectable nanomedicines market is expected to witness significant growth with CAGR pegged at 8.1% through 2026. Manufacturers of injectable nanomedicines are targeting chronic diseases and cancers.

Continue Reading
This image opens in the lightbox
Persistence Market Research Logo

Revenues from North America injectable nanomedicines market is expected to expand at significant CAGR and it is estimated to remain as dominant regional market for injectable nanomedicines due to large presence of hospitals and advanced healthcare facilities. Europe is also expected to be one of the leading regional markets for injectable nanomedicines as most of the major academic research institutes and R&D institutes for specialized drugs are located in the region. An ageing population and increasing prevalence of chronic illnesses is estimated to lead to rising demand for injectable nanomedicines.

Injectable nanomedicines are considered as an emerging field with many companies spending on R&D to explore this field in greater depth. There are both small and established market players investing in injectable nanomedicines. Majority of injectable nanomedicines were produced by small pharmaceutical companies which were later acquired by established market players. Small pharmaceutical companies are exploring nanotechnology to develop advanced drugs and technologies.  For instance, Pfizer collaborated with BIND Therapeutics Inc for the development of nanoparticles, called Accurins.

Request For Report Sample: https://www.persistencemarketresearch.com/samples/25999

The growing adoption of injectable nanomedicines for cancer treatment is expected to boost revenues generated from injectable nanomedicines thereby boost the growth of the global injectable nanomedicines market. Cancer is one of the leading causes of deaths globally, with approximately 1,688,780 new cases and 600,920 deaths in 2017. Researchers note that efficacy of traditional cancer therapeutics is often modest to negligible owing to the low specificity and stability. For obtaining optimal therapeutic effects, the right drug should be delivered at the targeted microenvironment at the right time with the right concentration.

Injectable nanomedicines are advantageous over all the conventional medicines for cancer therapy. Injectable nanomedicines contain drugs loaded in nanoparticles, which help to overcome the biological barriers, improve the efficacy and reduce morbidity.  These medicines further improve the bioavailability and toxicity profile of cancer treatments. All these factors are projected to drive the growth of the global injectable nanomedicines market during the forecast period.

The global injectable nanomedicines market is segmented based on drug type, applications, and end user.

Based on drug type, the injectable nanomedicines market has been segmented into liposomes, micelles, nanocrystals, polymeric nanoparticles, metallic nanoparticles, mesoporous silica nanoparticles and others. The liposomal drug type is projected to be the leading segment holding maximum share in the global injectable nanomedicines market. Liposomes mimic biological cells and are highly biocompatible, which makes them an ideal candidate for a drug delivery system among global injectable nanomedicines manufacturers.

Request for Report Methodology @: https://www.persistencemarketresearch.com/methodology/25999

Based on application, the injectable nanomedicines market has been segmented into cancer, central nervous system disease, cardiovascular disease, infection control, inflammatory disease and others. In terms of revenue, cancer application dominated the global injectable nanomedicines market in 2017 and is projected to continue to do so throughout the forecast period. After cancer, CNS application is expected to account for significant share in the market.

The global injectable nanomedicines market   is competitive, with large number of players. However, availability of adequate sterile drug manufacturing facilities is estimated to pose serious problem in injectable nanomedicines market throughout the forecast period, especially in emerging markets.

Examples of some of the key companies operating in the market are Pfizer Inc., Merck & Co, Inc., Lupin, Janssen Biotech Inc., Hoffmann-La Roche Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Pacira Pharmaceuticals Inc., Celgene Corporation and Bausch & Lomb Incorporated, among others.

Get full Report Now: https://www.persistencemarketresearch.com/checkout/25999

The information presented in this review is based on a PMR report, titled "Injectable Nanomedicines Market Segmentation by Key Players - Pfizer Inc., Merck & Co, Inc., Lupin, Janssen Biotech Inc., Hoffmann-La Roche Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Pacira Pharmaceuticals Inc., Celgene Corporation and Bausch & Lomb Incorporated- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026."

Popular Research Reports by PMR:

  • Dental Lasers Market Segmentations product types - dental welding laser, dental surgical lasers; By End User - hospitals, dental clinics, ambulatory surgical centers: https://www.persistencemarketresearch.com/market-research/dental-lasers-market.asp
  • Rosacea Treatment Market segmentations By Distribution Channel , By Drug Class- antimicrobials, alpha agonists, retinoid and others: https://www.persistencemarketresearch.com/market-research/rosacea-treatment-market.asp
  • Generic Oncology Drugs Market Segmentations By Molecule Type - large molecule , small molecule; By Route of Administration- Oral and Parenteral: https://www.persistencemarketresearch.com/market-research/generic-oncology-drugs-market.asp

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com  

PMR Latest News: https://www.persistencemarketresearch.com/news 

Related Links

https://www.persistencemarketresearch.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.